Ligand Pharmaceuticals (LGND) revenue breakdown
By product, Income from Pelthos Transaction is the largest at 20% of fiscal 2025 revenue; Filspari grew fastest, 247% a year over 2 years.
Revenue by product
Fiscal years, as Ligand Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $268M.
| Products | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income from Pelthos Transaction | — | — | — | — | — | — | — | — | — | $53M | 20% |
| Captisol | — | — | — | — | $25M | $23M | $104M | $28M | $31M | $40M | 15% |
| Kyprolis | — | — | — | — | — | — | — | $36M | $38M | $36M | 13% |
| Filspari | — | — | — | — | — | — | — | $3M | $12M | $32M | 12% |
| Qarziba | — | — | — | — | — | — | — | — | $11M | $24M | 9% |
| Rylaze | — | — | — | — | — | — | — | $14M | $14M | $13M | 5% |
| Other | — | — | — | — | — | — | — | $7M | $7M | $10M | 4% |
| Capvaxive | — | — | — | — | — | — | — | — | $626,000 | $10M | 4% |
| Ohtuvayre | — | — | — | — | — | — | — | — | $833,000 | $10M | 4% |
| Teriparatide injection | — | — | — | — | — | — | — | $11M | $8M | $8M | 3% |
| Vaxneuvance | — | — | — | — | — | — | — | $4M | $5M | $7M | 3% |
| Income | — | — | — | — | — | — | — | — | $2M | $7M | 3% |
| Contract revenue | — | — | — | — | — | — | $19M | $18M | $26M | $7M | 3% |
| Evomela | — | — | — | — | — | — | — | $10M | $9M | $6M | 2% |
| Other | — | — | — | — | — | — | — | $1M | $2M | $5M | 2% |
| Captisol - COVID | $23M | $22M | $29M | $31M | $85M | $141M | — | — | — | — | — |
| Royalties | $59M | $89M | $129M | — | — | — | — | — | — | — | — |
| Contract revenue | $27M | $30M | $94M | — | — | — | — | — | — | — | — |
| Revenue from intangible royalty assets | — | — | — | — | — | — | $73M | — | — | — | — |
| Kyprolis | — | — | — | $25M | $25M | $27M | — | — | — | — | — |
| Milestone | — | — | — | $17M | $5M | $18M | — | — | — | — | — |
| Promacta | — | — | — | $14M | — | — | — | — | — | — | — |
| Evomela | — | — | — | $5M | $6M | $10M | — | — | — | — | — |
| Other | — | — | — | $2M | $5M | $6M | — | — | — | — | — |
| Teriparatide injection | — | — | — | — | — | $5M | — | — | — | — | — |
| Service Revenue | — | — | — | $17M | $9M | $4M | — | — | — | — | — |
| Other | — | — | — | $3M | $2M | $4M | — | — | — | — | — |
| Rylaze | — | — | — | — | — | $2M | — | — | — | — | — |
| License Fees | — | — | — | $6M | $119,000 | $634,000 | — | — | — | — | — |
| Income from financial royalty assets | — | — | — | — | — | — | $385,000 | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for LGND.
Open LGND in InvestinglyQuestions
Where does Ligand Pharmaceuticals make its money?
In fiscal 2025, by product: Income from Pelthos Transaction $53M, Captisol $40M, Kyprolis $36M, Filspari $32M, Qarziba $24M.
From Ligand Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.